The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: Potential for therapeutics

Journal of Immunology

Volumn 185, Issue 4, 2010, Pages 2555-2562

  Karlberg, Mats ^a   Ekoff, Maria ^a   Huang, David C S ^b   Mustonen, Paula ^c   Harvima, Ilkka T ^c   Nilsson, Gunnar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; ABT-737; BAK1 PROTEIN, MOUSE; BAX PROTEIN, MOUSE; BIPHENYL DERIVATIVE; NITROPHENOL; PIPERAZINE DERIVATIVE; PROTEIN BAK; PROTEIN BAX; SULFONAMIDE;

ALLERGY; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; ASTHMA; CELL SURVIVAL; CHRONIC INFLAMMATION; CONFOCAL MICROSCOPY; DRUG SENSITIVITY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; MACROPHAGE; MALE; MAST CELL; MASTOCYTOSIS; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PERITONEUM; PERITONEUM CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BINDING; SKIN BIOPSY; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUSE MUTANT; ORGAN CULTURE TECHNIQUE; SKIN; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAST CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NITROPHENOLS; ORGAN CULTURE TECHNIQUES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN; SULFONAMIDES;

EID: 77956914323     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903656     Document Type: Article

References (50)

1. Nathan, C. 2002. Points of control in inflammation. Nature 420: 846-852.
2. Marshall, J. S. 2004. Mast-cell responses to pathogens. Nat. Rev. Immunol. 4: 787-799.
3. Galli, S. J., M. Grimbaldeston, and M. Tsai. 2008. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol. 8: 478-486.
4. Metz, M., and M. Maurer. 2007. Mast cells - key effector cells in immune responses. Trends Immunol. 28: 234-241.
5. Leslie, M. 2007. Mast cells show their might. Science 317: 614-616.
6. Harvima, I. T., G. Nilsson, M. M. Suttle, and A. Naukkarinen. 2008. Is there a role for mast cells in psoriasis? Arch. Dermatol. Res. 300: 461-478.
7. Benoist, C., and D. Mathis. 2002. Mast cells in autoimmune disease. Nature 420: 875-878.
8. Sun, J., G. K. Sukhova, P. J. Wolters, M. Yang, S. Kitamoto, P. Libby, L. A. MacFarlane, J. Mallen-St Clair, and G. P. Shi. 2007. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat. Med. 13: 719-724.
9. Soucek, L., E. R. Lawlor, D. Soto, K. Shchors, L. B. Swigart, and G. I. Evan. 2007. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 13: 1211-1218.
10. Metcalfe, D. D. 2008. Mast cells and mastocytosis. Blood 112: 946-956.
11. Lessene, G., P. E. Czabotar, and P. M. Colman. 2008. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug Discov. 7: 989-1000.
12. Hallett, J. M., A. E. Leitch, N. A. Riley, R. Duffin, C. Haslett, and A. G. Rossi. 2008. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. Trends Pharmacol. Sci. 29: 250-257.
13. Youle, R. J., and A. Strasser. 2008. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9: 47-59.
14. Willis, S. N., J. I. Fletcher, T. Kaufmann, M. F. van Delft, L. Chen, P. E. Czabotar, H. Ierino, E. F. Lee, W. D. Fairlie, P. Bouillet, et al. 2007. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
15. Huang, D. C. S., and A. Strasser. 2000. BH3-Only proteins-essential initiators of apoptotic cell death. Cell 103: 839-842.
16. van Delft, M. F., A. H. Wei, K. D. Mason, C. J. Vandenberg, L. Chen, P. E. Czabotar, S. N. Willis, C. L. Scott, C. L. Day, S. Cory, et al. 2006. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399.
17. Mekori, Y. A., A. M. Gilfillan, C. Akin, K. Hartmann, and D. D. Metcalfe. 2001. Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL. J. Clin. Immunol. 21: 171-174.
18. Hartmann, K., M. Artuc, S. E. Baldus, T. K. Zirbes, B. Hermes, J. Thiele, Y. A. Mekori, and B. M. Henz. 2003. Expression of Bcl-2 and Bcl-xL in cutaneous and bone marrow lesions of mastocytosis. Am. J. Pathol. 163: 819-826.
19. Möller, C., M. Karlberg, M. Åbrink, K. I. Nakayama, N. Motoyama, and G. Nilsson. 2007. Bcl-2 and Bcl-XL are indispensable for the late phase of mast cell development from mouse embryonic stem cells. Exp. Hematol. 35: 385-393.
20. Alfredsson, J., H. Puthalakath, H. Martin, A. Strasser, and G. Nilsson. 2005. Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-XL upon IgE-receptor activation. Cell Death Differ. 12: 136-144.
21. Ekoff, M., T. Kaufmann, M. Engström, N. Motoyama, A. Villunger, J. I. Jönsson, A. Strasser, and G. Nilsson. 2007. The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood 110: 3209-3217.
22. Möller, C., J. Alfredsson, M. Engström, H. Wootz, Z. Xiang, J. Lennartsson, J. I. Jönsson, and G. Nilsson. 2005. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood 106: 1330-1336.
23. Cragg, M. S., C. Harris, A. Strasser, and C. L. Scott. 2009. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat. Rev. Cancer 9: 321-326.
24. Kitada, S., C. L. Kress, M. Krajewska, L. Jia, M. Pellecchia, and J. C. Reed. 2008. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 111: 3211-3219.
25. Oltersdorf, T., S. W. Elmore, A. R. Shoemaker, R. C. Armstrong, D. J. Augeri, B. A. Belli, M. Bruncko, T. L. Deckwerth, J. Dinges, P. J. Hajduk, et al. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
26. Mohammad, R. M., A. S. Goustin, A. Aboukameel, B. Chen, S. Banerjee, G. Wang, Z. Nikolovska-Coleska, S. Wang, and A. Al-Katib. 2007. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin. Cancer Res. 13: 2226-2235.
27. Konopleva, M., R. Contractor, T. Tsao, I. Samudio, P. P. Ruvolo, S. Kitada, X. Deng, D. Zhai, Y. X. Shi, T. Sneed, et al. 2006. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388.
28. Mason, K. D., C. J. Vandenberg, C. L. Scott, A. H. Wei, S. Cory, D. C. Huang, and A. W. Roberts. 2008. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc. Natl. Acad. Sci. USA 105: 17961-17966.
29. Ullerå s, E., M. Karlberg, C. Möller Westerberg, J. Alfredsson, S. Gerondakis, A. Strasser, and G. Nilsson. 2008. NFAT but not NF-kappaB is critical for transcriptional induction of the prosurvival gene A1 after IgE receptor activation in mast cells. Blood 111: 3081-3089.
30. Willis, S. N., L. Chen, G. Dewson, A. Wei, E. Naik, J. I. Fletcher, J. M. Adams, and D. C. Huang. 2005. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 19: 1294-1305.
31. Ekoff, M., A. Strasser, and G. Nilsson. 2007. FcepsilonRI aggregation promotes survival of connective tissue-like mast cells but not mucosal-like mast cells. J. Immunol. 178: 4177-4183.
32. Kirshenbaum, A. S., C. Akin, Y. Wu, M. Rottem, J. P. Goff, M. A. Beaven, V. K. Rao, and D. D. Metcalfe. 2003. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk. Res. 27: 677-682.
33. Malbec, O., K. Roget, C. Schiffer, B. Iannascoli, A. R. Dumas, M. Arock, and M. Daëron. 2007. Peritoneal cell-derived mast cells: an in vitro model of mature serosal-type mouse mast cells. J. Immunol. 178: 6465-6475.
34. Kivinen, P. K., G. Nilsson, A. Naukkarinen, and I. T. Harvima. 2003. Mast cell survival and apoptosis in organ-cultured human skin. Exp. Dermatol. 12: 53-60.
35. Mason, K. D., M. R. Carpinelli, J. I. Fletcher, J. E. Collinge, A. A. Hilton, S. Ellis, P. N. Kelly, P. G. Ekert, D. Metcalf, A. W. Roberts, et al. 2007. Programmed anuclear cell death delimits platelet life span. Cell 128: 1173-1186.
36. Lindsten, T., A. J. Ross, A. King, W. X. Zong, J. C. Rathmell, H. A. Shiels, E. Ulrich, K. G. Waymire, P. Mahar, K. Frauwirth, et al. 2000. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell 6: 1389-1399.
37. Wei, M. C., W. X. Zong, E. H. Cheng, T. Lindsten, V. Panoutsakopoulou, A. J. Ross, K. A. Roth, G. R. MacGregor, C. B. Thompson, and S. J. Korsmeyer. 2001. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730.
38. Del Gaizo Moore, V., K. D. Schlis, S. E. Sallan, S. A. Armstrong, and A. Letai. 2008. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 111: 2300-2309.
39. Tahir, S. K., X. Yang, M. G. Anderson, S. E. Morgan-Lappe, A. V. Sarthy, J. Chen, R. B. Warner, S. C. Ng, S. W. Fesik, S. W. Elmore, et al. 2007. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 67: 1176-1183.
40. Tagscherer, K. E., A. Fassl, B. Campos, M. Farhadi, A. Kraemer, B. C. Böck, S. Macher-Goeppinger, B. Radlwimmer, O. D. Wiestler, C. Herold-Mende, and W. Roth. 2008. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27: 6646-6656.
41. Serhan, C. N., and J. Savill. 2005. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6: 1191-1197.
42. Zhang, H., P. M. Nimmer, S. K. Tahir, J. Chen, R. M. Fryer, K. R. Hahn, L. A. Iciek, S. J. Morgan, M. C. Nasarre, R. Nelson, et al. 2007. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 14: 943-951.
43. Bardwell, P. D., J. Gu, D. McCarthy, C. Wallace, S. Bryant, C. Goess, S. Mathieu, C. Grinnell, J. Erickson, S. H. Rosenberg, et al. 2009. The Bcl-2 family antagonist ABT-737 significantly inhibits multiple animal models of autoimmunity. J. Immunol. 182: 7482-7489.
44. Chen, S., Y. Dai, H. Harada, P. Dent, and S. Grant. 2007. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 67: 782-791.
45. Cohen-Saidon, C., H. Nechushtan, S. Kahlon, N. Livni, A. Nissim, and E. Razin. 2003. A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival. Blood 102: 2506-2512.
46. Aichberger, K. J., M. Mayerhofer, K. V. Gleixner, M. T. Krauth, A. Gruze, W. F. Pickl, V. Wacheck, E. Selzer, L. Müllauer, H. Agis, et al. 2007. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 109: 3031-3041.
47. Fischer, M., I. T. Harvima, R. F. S. Carvalho, C. Möller, A. Naukkarinen, G. Enblad, and G. Nilsson. 2006. Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J. Clin. Invest. 116: 2748-2756.
48. Letai, A. 2005. Pharmacological manipulation of Bcl-2 family members to control cell death. J. Clin. Invest. 115: 2648-2655.
49. Pope, R. M. 2002. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat. Rev. Immunol. 2: 527-535.
50. Tse, C., A. R. Shoemaker, J. Adickes, M. G. Anderson, J. Chen, S. Jin, E. F. Johnson, K. C. Marsh, M. J. Mitten, P. Nimmer, et al. 2008. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68: 3421-3428.